-
公开(公告)号：US20240075165A1
公开(公告)日：2024-03-07
申请号：US17988742
申请日：2022-11-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K48/00 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/00 , A61K39/12 , A61K39/215 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34
CPC classification number: A61K48/0066 , A61K9/0019 , A61K9/1271 , A61K9/5123 , A61K9/5146 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/0011 , A61K39/12 , A61K39/215 , A61K48/0033 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00 , A61K2039/53 , A61K2039/54 , A61K2039/545 , C12N2770/18022 , C12N2770/18034 , C12N2770/18071 , C12N2770/20034
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US20230075979A1
公开(公告)日：2023-03-09
申请号：US17698829
申请日：2022-03-18
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K39/215 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K9/51 , A61P31/14 , C12N15/11 , C12N15/67 , C12N15/88
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US12133899B2
公开(公告)日：2024-11-05
申请号：US17988742
申请日：2022-11-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K48/00 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/00 , A61K39/12 , A61K39/215 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US20240002127A1
公开(公告)日：2024-01-04
申请号：US17920569
申请日：2021-04-16
Applicant: Pfizer Inc. , BioNTech SE
Inventor： Marjoh Nauta , Dirk Jozef Peeters , Tom Frank Steven Van Doorslaer , Advait Vijay Badkar , Ramin Darvari , Nicholas William Warne , James Jean , Danny Pierre G. Hendrikse , Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: B65D81/127 , A61K39/215 , B65D77/04 , B65D81/38
CPC classification number: B65D81/127 , A61K39/215 , A61K2039/55555 , B65D81/3813 , B65D77/0413
Abstract: The present disclosure relates to the fields of packaging, transportation, and storage of temperature-sensitive materials, such as biological and/or pharmaceutical products. Various aspects of such packaging, transportation, and storage are provided herein for ultra-low temperature materials useful for the treatment and/or prevention of disease. The present disclosure also provides packaging materials, methods of transportation, and methods of storage for maintaining biological and/or pharmaceutical materials at ultra-low temperatures in order to maintain the integrity of the materials. The present disclosure further relates to the field of RNA to prevent or treat coronavirus infection.
-
公开(公告)号：US20220313811A1
公开(公告)日：2022-10-06
申请号：US17717645
申请日：2022-04-11
Applicant: BIONTECH SE , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Inventor： Ugur Sahin , Heinrich Haas , Annette Vogel , Daniel Zucker , Stephanie Erbar , Kerstin Walzer , Anne Schlegel , Sebastian Hörner , Sebastian Kreiter , Mustafa Diken , Jorge Moreno Herrero
Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.
-
Patent Agency Ranking
公开(公告)号：US12150947B2
公开(公告)日：2024-11-26
申请号：US16957898
申请日：2019-01-10
Applicant: BioNTech SE , TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GGMBH
Inventor： Ugur Sahin , Heinrich Haas , Annette Vogel , Stephanie Erbar , Kerstin Walzer , Anne Schlegel , Sebastian Hörner , Jorge Herrero Moreno , Thorsten Klamp , Sebastian Kreiter , Mustafa Diken , Phillip Heller
IPC: A61K31/70 , A61K9/00 , A61K35/763 , A61K47/18
Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.
-
公开(公告)号：US20230073461A1
公开(公告)日：2023-03-09
申请号：US17699035
申请日：2022-03-18
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K39/12 , A61K31/7105 , A61K31/7115 , A61K31/712 , A61K9/127 , A61K9/51 , A61P31/14 , B82Y5/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US11547673B1
公开(公告)日：2023-01-10
申请号：US17233396
申请日：2021-04-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US20220249704A1
公开(公告)日：2022-08-11
申请号：US17565842
申请日：2021-12-30
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci , Gábor Boros , Azita Josefine Mahiny , Jonas Reinholz , Katalin Karikó
IPC: A61K48/00 , A61P35/00 , A61K39/00 , A61K31/7088 , A61K39/12
Abstract: Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.
-
公开(公告)号：US11925694B2
公开(公告)日：2024-03-12
申请号：US17698829
申请日：2022-03-18
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61P31/14 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/00 , A61K39/12 , A61K39/215 , A61K48/00 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00
CPC classification number: A61K48/0066 , A61K9/0019 , A61K9/1271 , A61K9/5123 , A61K9/5146 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/0011 , A61K39/12 , A61K39/215 , A61K48/0033 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55555 , C12N2770/18022 , C12N2770/18034 , C12N2770/18071 , C12N2770/20034 , C12N2840/00
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.021 seconds)
